2026 Q1 -tulosraportti
27 päivää sitten
‧29 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 540 | - | - | ||
| 3 137 | - | - | ||
| 149 | - | - | ||
| 108 | - | - | ||
| 43 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sittenI would like to make a correction to how it works when Bioporto sells NGAL tests for adults, only for research use. I have previously stated that Bioporto will sell NGAL tests for adults, only for research, to American hospitals, even though the FDA has not yet approved the test, and that is also correct, but I had understood that it was a gray area that the hospitals were moving into, and that is incorrect. The correct information is. If a hospital in the USA has a laboratory that is advanced enough and approved by the FDA for research, such as NGAL tests for adults, then it is completely legal. They call it CLIA. In the USA there are 490 university hospitals, all of which are allowed to use the NGAL test, only for research. Some of these university hospitals own a number of smaller hospitals and other treatment centers, and they can also use the NGAL test for adults, because the university hospitals run the test for them. The purely public hospitals must politely wait until the NGAL test for adults is approved by the FDA. That is the reason why Bioporto maintains its expectations and holds on to 60+ hospitals. CLIA https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf Number of university hospitals https://www.aamc.org/about-us/institutional-membership Example of a university hospital that owns smaller treatment centers https://www.massgeneralbrigham.org/en/patient-care/services-and-specialties/find-a-location/our-hospitals- ·16 t sitten
·1 päivä sitten · MuokattuWithin a couple of days, the 50-day simple moving average (SMA 50) will cross up through the SMA 200. This is called a Golden Cross, and is a strong signal that the stock has reversed a negative/flat trend and is now in a strong upward trend. There are people who swear by TA, so it will be interesting to follow the price over the next couple of days.·19 t sittenmuldyr, even though I am not a TA myself, I often look at what the TAs say. I think one should, as many trade based on TA and consequently can affect the price. In the case of BP, however, I don't attach much importance to TA. The reason is the low turnover. It is indeed low, so even a private investor, so to speak, can order the TA formation he desires, which I think undermines TA a bit here. But we'll see. The delay and significant extra cost BP just received as a gift from the FDA is a setback and a slap that can be felt in little fragile BP. If TAs think it should go up on that, be my quest.
·10.6.From DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
27 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenI would like to make a correction to how it works when Bioporto sells NGAL tests for adults, only for research use. I have previously stated that Bioporto will sell NGAL tests for adults, only for research, to American hospitals, even though the FDA has not yet approved the test, and that is also correct, but I had understood that it was a gray area that the hospitals were moving into, and that is incorrect. The correct information is. If a hospital in the USA has a laboratory that is advanced enough and approved by the FDA for research, such as NGAL tests for adults, then it is completely legal. They call it CLIA. In the USA there are 490 university hospitals, all of which are allowed to use the NGAL test, only for research. Some of these university hospitals own a number of smaller hospitals and other treatment centers, and they can also use the NGAL test for adults, because the university hospitals run the test for them. The purely public hospitals must politely wait until the NGAL test for adults is approved by the FDA. That is the reason why Bioporto maintains its expectations and holds on to 60+ hospitals. CLIA https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf Number of university hospitals https://www.aamc.org/about-us/institutional-membership Example of a university hospital that owns smaller treatment centers https://www.massgeneralbrigham.org/en/patient-care/services-and-specialties/find-a-location/our-hospitals
- ·16 t sitten
- ·1 päivä sitten · MuokattuWithin a couple of days, the 50-day simple moving average (SMA 50) will cross up through the SMA 200. This is called a Golden Cross, and is a strong signal that the stock has reversed a negative/flat trend and is now in a strong upward trend. There are people who swear by TA, so it will be interesting to follow the price over the next couple of days.·19 t sittenmuldyr, even though I am not a TA myself, I often look at what the TAs say. I think one should, as many trade based on TA and consequently can affect the price. In the case of BP, however, I don't attach much importance to TA. The reason is the low turnover. It is indeed low, so even a private investor, so to speak, can order the TA formation he desires, which I think undermines TA a bit here. But we'll see. The delay and significant extra cost BP just received as a gift from the FDA is a setback and a slap that can be felt in little fragile BP. If TAs think it should go up on that, be my quest.
- ·10.6.From DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 540 | - | - | ||
| 3 137 | - | - | ||
| 149 | - | - | ||
| 108 | - | - | ||
| 43 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
27 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenI would like to make a correction to how it works when Bioporto sells NGAL tests for adults, only for research use. I have previously stated that Bioporto will sell NGAL tests for adults, only for research, to American hospitals, even though the FDA has not yet approved the test, and that is also correct, but I had understood that it was a gray area that the hospitals were moving into, and that is incorrect. The correct information is. If a hospital in the USA has a laboratory that is advanced enough and approved by the FDA for research, such as NGAL tests for adults, then it is completely legal. They call it CLIA. In the USA there are 490 university hospitals, all of which are allowed to use the NGAL test, only for research. Some of these university hospitals own a number of smaller hospitals and other treatment centers, and they can also use the NGAL test for adults, because the university hospitals run the test for them. The purely public hospitals must politely wait until the NGAL test for adults is approved by the FDA. That is the reason why Bioporto maintains its expectations and holds on to 60+ hospitals. CLIA https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf Number of university hospitals https://www.aamc.org/about-us/institutional-membership Example of a university hospital that owns smaller treatment centers https://www.massgeneralbrigham.org/en/patient-care/services-and-specialties/find-a-location/our-hospitals
- ·16 t sitten
- ·1 päivä sitten · MuokattuWithin a couple of days, the 50-day simple moving average (SMA 50) will cross up through the SMA 200. This is called a Golden Cross, and is a strong signal that the stock has reversed a negative/flat trend and is now in a strong upward trend. There are people who swear by TA, so it will be interesting to follow the price over the next couple of days.·19 t sittenmuldyr, even though I am not a TA myself, I often look at what the TAs say. I think one should, as many trade based on TA and consequently can affect the price. In the case of BP, however, I don't attach much importance to TA. The reason is the low turnover. It is indeed low, so even a private investor, so to speak, can order the TA formation he desires, which I think undermines TA a bit here. But we'll see. The delay and significant extra cost BP just received as a gift from the FDA is a setback and a slap that can be felt in little fragile BP. If TAs think it should go up on that, be my quest.
- ·10.6.From DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 540 | - | - | ||
| 3 137 | - | - | ||
| 149 | - | - | ||
| 108 | - | - | ||
| 43 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt